We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Novavax (NVAX - Free Report) . Shares have lost about 42.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Novavax due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Novavax's Earnings Beat in Q2, Sales Lag Estimates
Novavax recorded second-quarter 2020 loss per share of 30 cents, narrower than the Zacks Consensus Estimate of a loss of 57 cents and also the year ago quarter’s loss of $1.69.
Revenues in the quarter were $36 million, reflecting a significant increase year over year owing to the CEPI’s funding related to the clinical development of NVX-CoV2373. However, the top line missed the Zacks Consensus Estimate of $46 million.
Revenues for the three months ended Jun 30, 2020 included revenues under the CEPI grant. The company expects revenues to significantly rise in 2020 owing to its NVX-CoV2373 program, which will be primarily funded by CEPI and other potential non-dilutive funding sources, namely the department of defense and US government under Operation Warp Speed
Quarter in Detail
In the reported quarter, research and development expenses were $34.8 million, up 15% from the year-ago figure due to higher costs for the development of NVX-CoV2373.
General and administrative expenses rose 84% to $17.7 million due to higher professional fees and employee-related expenses
As of Jun 30, 2020, Novavax had cash, cash equivalents, marketable securities and restricted cash worth $609.5 million compared with $244.7 million as of Mar 31, 2020.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -10.51% due to these changes.
VGM Scores
Currently, Novavax has a strong Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Novavax has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?
A month has gone by since the last earnings report for Novavax (NVAX - Free Report) . Shares have lost about 42.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Novavax due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Novavax's Earnings Beat in Q2, Sales Lag Estimates
Novavax recorded second-quarter 2020 loss per share of 30 cents, narrower than the Zacks Consensus Estimate of a loss of 57 cents and also the year ago quarter’s loss of $1.69.
Revenues in the quarter were $36 million, reflecting a significant increase year over year owing to the CEPI’s funding related to the clinical development of NVX-CoV2373. However, the top line missed the Zacks Consensus Estimate of $46 million.
Revenues for the three months ended Jun 30, 2020 included revenues under the CEPI grant. The company expects revenues to significantly rise in 2020 owing to its NVX-CoV2373 program, which will be primarily funded by CEPI and other potential non-dilutive funding sources, namely the department of defense and US government under Operation Warp Speed
Quarter in Detail
In the reported quarter, research and development expenses were $34.8 million, up 15% from the year-ago figure due to higher costs for the development of NVX-CoV2373.
General and administrative expenses rose 84% to $17.7 million due to higher professional fees and employee-related expenses
As of Jun 30, 2020, Novavax had cash, cash equivalents, marketable securities and restricted cash worth $609.5 million compared with $244.7 million as of Mar 31, 2020.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -10.51% due to these changes.
VGM Scores
Currently, Novavax has a strong Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Novavax has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.